Maze Therapeutics (NASDAQ:MAZE) Shares Up 6.8% - Here's What Happened

Key Points

• Maze Therapeutics' stock price increased by 6.8%, closing at $15.48, with a notable trading volume of 254,148 shares, surpassing the average session volume by 18%.
• Analysts maintain a positive outlook, with HC Wainwright and BTIG Research issuing "buy" ratings and price targets of $34.00 and $30.00 respectively, contributing to an average target price of $26.33.
• The company recently reported earnings of ($0.77) per share, beating the consensus estimate and indicating a strong financial performance for the quarter.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shot up 6.8% during mid-day trading on Tuesday . The company traded as high as $15.60 and last traded at $15.48. 254,148 shares were traded during trading, an increase of 18% from the average session volume of 215,089 shares. The stock had previously closed at $14.49.

Analyst Ratings Changes

A number of research firms have weighed in on MAZE. HC Wainwright started coverage on shares of Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price objective for the company. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target on the stock. Finally, BTIG Research began coverage on Maze Therapeutics in a report on Tuesday. They issued a "buy" rating and a $30.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $26.33.

Maze Therapeutics Trading Up 5.6%

The business has a fifty day simple moving average of $14.55 and a 200 day simple moving average of $12.01.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.02.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after buying an additional 438,274 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Maze Therapeutics in the 2nd quarter valued at $125,000. Bank of America Corp DE lifted its stake in Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after acquiring an additional 1,455 shares in the last quarter. Finally, CW Advisors LLC acquired a new position in Maze Therapeutics during the 2nd quarter worth about $371,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.